Now is the time...

If you are a healthy older adult with normal memory, this could be the right time for you to join the fight to prevent the memory loss of Alzheimer’s disease.

What is the A4 Study?

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study” for short) is a clinical study for older individuals (65 to 85 years of age) who may be at risk for memory loss due to Alzheimer’s disease (AD).

The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.

The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.

Am I eligible?

• The A4 study will enroll 1,000 people between the ages of 65 through 85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain.

• Physicians and researchers will use PET amyloid imaging scans to determine whether a potential participant has evidence of elevated amyloid buildup

• Individuals with elevated amyloid on the PET scan will be eligible to become participants in the A4 clinical study.

• People who do not show evidence of elevated brain amyloid may be asked to participate in a separate study. This group will not receive the study drug but will complete the same memory tests every six months to compare changes in cognition over time.

Interested in learning more about A4?

Call or email the National Institute on Aging
1-800-438-4380
Mon – Fri, 8:30 am to 5:00 pm Eastern
email: adear@nia.nih.gov
visit: a4study.org

Kendra Bates
University of Kentucky
Sanders-Brown Center on Aging
Alzheimer’s Disease Center
(859) 327-5562
Kendra.Bates@uky.edu